A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma
Ajai Chari(University of California, San Francisco), Samir Parekh(The Ohio State University Wexner Medical Center)
Cited by 60
Related Papers
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma
|Cancer Cell|2021|216
Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy
|Blood|2022|103